Drug Profile

ZVS 101e

Alternative Names: rAAV2/8-hCYP4V2; rAAV8-hCYP4V2; ZVS-101e

Latest Information Update: 01 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chigenovo
Class Eye disorder therapies; Gene therapies
Mechanism of Action CYP4V2 protein replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Bietti crystalline dystrophy
New Molecular Entity No

Highest Development Phases

Phase III Bietti crystalline dystrophy

Most Recent Events

29 Dec 2025 Chigenovo initiates enrolment in a clinical trial for Bietti crystalline dystrophy in China (Subretinal) (NCT07307469)
20 Dec 2024 Phase-III clinical trials in Bietti crystalline dystrophy in China (Subretinal) (NCT06743646)
29 Apr 2023 Adverse events data from a phase I trial in Bietti crystalline dystrophy released by Chinagene

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com